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A compendium of long non-coding 
RNAs transcriptional fingerprint in 
multiple myeloma
Domenica Ronchetti1,2, Luca Agnelli1,2, Alessandro Pietrelli3,4, Katia Todoerti1, Martina 
Manzoni  1,2, Elisa Taiana1,2 & Antonino Neri1,2
Multiple myeloma (MM) is a clonal proliferation of bone marrow plasma cells characterized by highly 
heterogeneous genetic background and clinical course, whose pathogenesis remains largely unknown. 
Long ncRNAs (lncRNAs) are a large class of non-protein-coding RNA, involved in many physiological 
cellular and genomic processes as well as in carcinogenesis and tumor evolution. Although still in its 
infancy, the role of lncRNAs in MM is progressively expanding. Besides studies on selected candidates, 
lncRNAs expression at genome-wide transcriptome level is confined to microarray technologies, 
thus investigating a limited collection of transcripts. In the present study investigating a cohort of 
30 MM patients, a deep RNA-sequencing analysis overwhelmed previous array studies and allowed 
the most accurate definition of lncRNA transcripts structure and expression, ultimately providing a 
comprehensive catalogue of lncRNAs specifically associated with the main MM molecular subgroups 
and genetic alterations. Despite the small number of analyzed samples, the high accuracy of RNA-
sequencing approach for complex transcriptome processing led to the identification of 391 deregulated 
lncRNAs, 67% of which were also detectable and validated by whole-transcript microarrays. In addition, 
we identified a list of lncRNAs, with potential relevance in MM, co-expressed and in close proximity to 
genes that might undergo a cis-regulatory relationship.
Multiple myeloma (MM) is an uncontrolled proliferation of Ig-secreting plasma cells (PCs) that accounts for 10% 
of all hematological tumors with incidence in Western countries of about 3–5 per 100,000. Despite the extraordi-
nary progresses in the diagnosis and treatment of the disease1, MM remains still incurable.
At the genetic level, MM is characterized by both numerical and structural chromosomal alterations, i.e. 
translocations affecting immunoglobulin heavy chain (IGH) locus and a number of oncogenic partners, hyper-
diploidy (HD), deletions of 13q and 17p13, and gain of 1q2. In addition, whole genome/exome sequencing analy-
ses recently evidenced somatic mutations occurring in genes with putative pathogenetic role, such KRAS, NRAS, 
TP53, BRAF, TRAF3, FAM46C and DIS33,4.
To date, many efforts have been undertaken to investigate the different molecular types of MM, aimed at 
understanding the clinical heterogeneity of the disease and promptly/easily identifying patients more prone to 
disease progression or relapse. Starting from global coding-gene expression profiling of purified myeloma PCs, 
it became possible to identify peculiar tumor-associated transcriptional profiles discriminating between normal 
and tumor phenotypes, or specifically associated with distinct MM molecular subtypes with different prognosis5,6. 
Afterwards, the increasing discovery of non-coding RNAs (ncRNAs), following human genome sequencing, have 
been changing the landscape of cancer biology. Focusing on MM, the investigations on small nucleolar RNA 
and mostly microRNAs (miRNAs), have greatly contributed to shed light into the molecular mechanism of the 
pathology and provide some new potential molecular targets7–10.
More recently, great attention has been dedicated to the heterogeneous group of long non-coding RNAs (lncR-
NAs). Genome-wide transcriptional studies carried out by ENCODE (Encyclopedia of DNA Elements) and other 
large international consortia have revealed that more than 90% of mammalian genomes is transcribed and that a 
great part of the transcripts are lncRNAs11–13. The GENCODE consortium14 has arranged a comprehensive set of 
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human lncRNAs and analyzed their genomic organization, modifications, cellular localizations and tissue expres-
sion profiles in different human cell line. LncRNAs contribute to several processes, e.g. maintenance of genomic 
integrity, X-chromosome inactivation, transcriptional regulation, genomic imprinting, cell differentiation and 
development15,16. Several lncRNAs have also been described to contribute to tumor formation and/or progression, 
as well as to metastatic processes, in many solid and hematologic tumors17,18, showing either oncogenic or tumor 
suppressive function.
Although the investigation of lncRNA in MM is still in its beginnings, our understanding of their role is 
progressively expanding. One of the most investigated lncRNA is MALAT1, deregulated in many solid tumors 
with a putatively oncogenic function19,20. MALAT1 is overexpressed in MM, where it has been shown to predict 
tumor progression21. Recent researches in MM have been focused on single lncRNAs already known as involved 
in different types of cancers, such as MEG3 functioning as tumor suppressor through both p53-dependent and 
p53-independent mechanisms22, or CRNDE overexpressed in association with poor clinical outcome23. Besides 
studies on selected candidates, lncRNA expression at genome-wide transcriptome level has been scarcely inves-
tigated in MM and the only two efforts reported so far are based on microarray data. In particular, Zhou et al.24 
investigated a repertoire of 2,330 lncRNAs in a publicly available clinically annotated cohort of 559 MM patients 
generating a four-lncRNA prognostic signature. In a previous study, our group analyzed the transcriptional pat-
terns of 1,852 lncRNAs in 259 patients affected by the different forms of PC dyscrasia at onset, included in pro-
prietary and publicly available datasets, identifying a series of deregulated lncRNAs associated either with disease 
progression or distinct molecular subgroups of MM25. However, these studies are limited to the detection of a 
relatively small number of sequences queried by the arrays, which were primarily designed to detect the coding 
transcriptome. Next-generation RNA sequencing (RNA-seq) addresses this shortcoming, but to date such an 
approach has not yet been pursued in MM.
In the present study, we investigated the lncRNA expression profiling in MM patients by RNA-seq, with the 
aim of providing a first exhaustive catalogue of lncRNAs specifically associated with the main molecular sub-
groups and genetic alterations in MM. Furthermore, we defined a repertoire of lncRNAs possibly involved in 
MM, as they meet the requirements of being both co-expressed and in close proximity to genes that have been 
described as relevant to this neoplasia, thus suggestive of a cis-regulatory relationship.
Overall, such a compendium and the free availability of RNA-seq data may provide the scientific community 
with valuable references for future research into the involvement of lncRNAs in MM.
Results
LncRNAs expression profile in multiple myeloma. The expression profile of lncRNAs has been inves-
tigated by RNA-seq in a cohort of 30 MM patients at diagnosis, whose molecular features were representative of 
those mainly characterizing the disease (Table 1).
We used a custom pipeline, based on the GENCODE encyclopedia that considered only those genes with 
unambiguously mapped transcripts, that allowed to annotate 14,202 lncRNAs; among them, we investigated the 
9,540 lncRNAs detectable upon removal of those unexpressed across the whole dataset. Overall, lncRNAs are 
scarcely expressed. Indeed, for each lncRNA the sum of the read counts in the 30 samples spans a wide range 
of values (from 2 to 6,707,843; median: 57). However, 86% of the 9,540 lncRNAs have average read counts <30, 
whereas only 1% of lncRNAs show average values > 500. Notably, 12 lncRNAs are very highly expressed display-
ing an average read counts >5000, counting 64% of the reads assigned to lncRNAs (Supplementary Table S1); in 
particular, this group includes NEAT1, MALAT1, MIAT and TUG1 frequently deregulated in malignant B-cells26. 
Based on the rationale that a single cis-acting molecule might be able to target effectively a neighboring locus, 
thus suggesting that even low expressed lncRNAs may have a key regulatory role27, we considered all the 9,540 
detectable lncRNAs for subsequent investigations.
To identify MM patient subgroups, we used an unsupervised-learning method based on expression data. This 
analysis showed clusters of common global lncRNAs transcriptional patterns that were associated with the major 
and prognostically relevant molecular features, namely t(11;14), t(4;14), MAF gene translocations or HD status. 
Sample Features Positive (%) Negative (%) Not available
HD 8 (27) 20 (67) 2
t(11;14) 8 (27) 22 (73) 0
t(4;14) 7 (23) 23 (77) 0
MAF-trx 4 (13) 26 (87) 0
del(17) 3 (10) 27 (90) 0
del(13) 18 (60) 12 (40) 0
1q-gain 15 (50) 13 (43) 2
N-RAS 3 (10) 20 (67) 7
K-RAS 7 (23) 16 (53) 7
BRAF 4 (13) 19 (63) 7
DIS3 6 (20) 17 (57) 7
P53 2(6) 20(67) 8
FAM46C 1(3) 21(70) 8
Table 1. Molecular characteristics of 30 MM patients.
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In fact, unsupervised analysis of the 500 lncRNAs with the highest variation coefficient clearly showed that MM 
molecular subtypes were mainly and significantly clustered together (Fig. 1a). Next, we compared the lncRNAs 
expression profiles of each subgroups against all the other samples. We found the significant deregulation of 
150 lncRNAs (116 down- and 34 up-regulated) in MM samples with HD status; 118 lncRNAs (68 down- and 
50 up-regulated) characterized patients with t(11;14) translocation; and 96 lncRNAs (34 downregulated and 62 
upregulated) MM carrying t(4;14). Finally, 42 lncRNAs (26 downregulated and 16 upregulated) defined MM with 
translocated MAF gene. Overall, we identified 391 unique lncRNAs differentially expressed among the four MM 
subgroups (Fig. 1b and Supplementary Table S2). Because the 30 MM investigated by RNA-seq had been previ-
ously profiled onto GeneChip® Human Gene 2.0 ST array together with 4 normal control, we verified whether 
that 391-lncRNA signature could be validated in the same cohort of patients assessed with a different technique. 
To this end, we evaluated the expression of the 262 of 391 lncRNAs detectable by the arrays, equally annotated on 
unambiguous entries in GENCODE encyclopedia. Overall, the dendrogram generated on the 262-lncRNA list 
clearly distinguished the diverse molecular subtypes and the normal samples (Mantel-Haenszel chi-squared test 
p < 0.00001; Fig. 2).
The five most significant differentially expressed lncRNAs in each comparison are reported in Table 2. As 
regards MM carrying t(11;14), of note, the three most significantly downregulated lncRNAs belonged to a cluster 
of 6 transcripts located in a region of about 332 kb at 19q12 (Fig. 3a and Supplementary Table S2). In addition, this 
group showed also the downregulation of MIAT (Fig. 3b–d), a well-known lncRNA already reported as involved 
in different cancers.
Figure 1. LncRNAs expression profiling in multiple myeloma. (a) Hierarchical agglomerative clustering of the 
30 patients based on the 500 most variably expressed lncRNAs. Under each branch, hyperdiploid status (HD), 
t(11;14), t(4;14) or MAF translocation (trx) occurrence are specified with the corresponding p-values. For each 
MM sample, positivity (grey), negativity (white) or “not determined” (light grey) for the different molecular 
features are indicated. (b) Heatmap of the most differentially expressed lncRNAs (rows) in the 30 MM patients 
(columns) stratified into five groups according to their molecular features. The color scale spans the relative 
transcript expression changes standardized on the variance.
www.nature.com/scientificreports/
4SCIeNtIFIC RePoRTs |  (2018) 8:6557  | DOI:10.1038/s41598-018-24701-8
Figure 2. LncRNAs expression validation by microarray analysis. Hierarchical clustering (Pearson’s 
correlation and centroid as distance and linkage methods) of the 30 samples and 4 normal controls profiled 
on GeneChip® Human Gene 2.0ST arrays according to the expression values of the 262-lncRNA list. Under 
each branch, hyperdiploid status (HD), t(11;14), t(4;14) or MAF translocation (MAF trx) are specified with the 
corresponding p-values.
Ensembl gene id Base Mean Stat Chr Start position End position Gene name
HD vs not 
HD
ENSG00000271856 324.13 − 6.23 3 108125821 108138610 LINC01215
ENSG00000245330 13.68 − 5.77 8 119867419 119874488 KB-1471A8.1
ENSG00000235919 131.25 − 5.52 1 155562042 155563944 ASH1L-AS1
ENSG00000253364 22406.66 5.56 14 105644496 105649057 RP11-731F5.2
ENSG00000260401 30.18 5.52 11 73238975 73242335 RP11-800A3.4
t(11;14) vs 
not (11;14)
ENSG00000267243
ENSG00000260725
ENSG00000260725
146
59.64
17.67
− 10.06
− 9.12
− 7.19
19
28437060
28418483
28491864
28535277
28429490
28632728
AC005307.4
AC005307.1
AC005616.1
ENSG00000260807 212.12 9.2 16 975761 981596 RP11-161M6.2
ENSG00000174171 138.72 7.045 15 41892793 41898575 RP11-23P13.6
ENSG00000260244 108.55 − 6.82 4 155734448 155737062 AC005616.1
ENSG00000225783 11802.7 − 6.41 22 26646428 26676475 MIAT
t(4;14) vs 
not (4;14)
ENSG00000236154 6.21 10.18 10 69575807 69577154 RP11-343J3.2
ENSG00000265778 2.72 8.08 18 76491652 76493918 RP11-17M16.2
ENSG00000235597 4.64 7.84 2 104433267 104520832 LINC01102
ENSG00000274307 3.05 7.13 15 25708470 25710869 RP11-345J18.2
ENSG00000204832 58.68 − 6.88 10 17386936 17413503 ST8SIA6-AS1
trx MAF 
vs not trx 
MAF
ENSG00000258776 30.07 11.51 14 56817570 56893710 RP11-1085N6.5
ENSG00000234184 1252.1 − 9.2 1 80535755 80646788 RP5-887A10.1
ENSG00000261997 16.59 9.21 16 55538200 55542027 RP11-212I21.4
ENSG00000270069 752.24 − 7.28 X 45745211 45770274 MIR222HG
ENSG00000185433 49.38 6.07 21 25385820 25431701 LINC00158
Table 2. Top five lncRNAs significantly deregulated in distinct MM subgroups (Base Mean = median 
expression among samples; Stat = DEseq algorithm statistic).
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Identification of lncRNA signatures associated with genetic lesions or somatic mutations. 
Other genetic alterations occur at high frequency in MM and were associated by others and us to specific tran-
scriptional profiles. Information was available for the 30 MM sample on numerical alterations and secondary 
events, i.e. somatic mutations (Table 1): therefore, we queried the RNA-seq dataset to evaluate the occurrence of 
differentially expressed lncRNAs in those MM genetic subtypes (Supplementary Table S3, with the exclusion of 
FAM46C and P53 due to the low number of samples).
In MM patients with 1q gain, we found the significant modulation of 12 lncRNAs (4 down- and 8- upregu-
lated), two of which located on chromosome 1q. A list of 109 lncRNAs (31 down- and 78 up-regulated) distin-
guished del(13)-positive from wild-type patients; notably, 7 of 31 downregulated lncRNAs (23%) are located on 
chromosome 13. Finally, only two lncRNAs have been found downregulated in del(17)-MM.
As regards patients harboring the mutations of BRAF, NRAS, KRAS, or DIS3 mutations, we identified the 
upregulation of 97 lncRNAs in DIS3 mutated samples, whereas 6 lncRNAs are upregulated in the samples 
grouped according to the presence of MAPK-pathway genes mutations.
Selection of lncRNAs potentially relevant in MM. After the annotation process, we established a set 
of criteria to recognize the lncRNAs potentially relevant in MM biology. In particular, we investigated the levels 
of expression of lncRNAs localized in proximity to genes associated with MM, based on the recurrent evidence 
that the transcription of mRNAs and lncRNAs appears to be closely regulated, leading to a cis-regulatory rela-
tionship between the two transcripts28–30. For this purpose, a list of 707 genes mapped to GRCh38 primary 
assembly and associated with MM (from now on, referred as “MM-genes”) was downloaded from NCBI data-
base (https://www.ncbi.nlm.nih.gov/gene, Supplementary Table S4). We analyzed the genomic context of the 
707 MM-genes. In the boundaries of 409 of them, we found at least one of the 9,540 lncRNAs mapped within 
4 Mb (Supplementary Table S4). Next, for each lncRNA/MM-gene couples we assessed the correlation of their 
Figure 3. MM patients with t(11;14) downregulated a cluster of 6 transcripts at 19q12 and MIAT. (a) 
Screenshot of the 19q12 region from GENCODE browser of GRCh38/hg38 genome release. Red boxes 
indicated the lncRNAs significantly downregulated in t(11;14) MM. (b) Visualization of RNA-seq data: 
zoomed view of the MIAT lncRNA region; the coverage bigWig files generated using bamCoverage function 
in deeptools (http://deeptools.readthedocs.io/en/latest/content/tools/bamCoverage.html) and the human 
genome annotation file (GENCODE v.25) were loaded into the Integrated Genome Viewer (IGV [http://www.
broadinstitute.org/igv/]. The y axis shows the scaled number of reads mapping to each location of the genome 
in the MIAT region (x axis); each lane represents a MM patient: samples t(11;14)-positive are shown in red. In 
order to compare samples, coverage values from all patients were group-scaled. (c) Correlation plot of MIAT 
expression in the 30 MM investigated by RNA-seq and GeneChip® Human Gene 2.0ST array. Red circle 
indicates t(11;14)-positive MM samples. (d) Box plot representation of MIAT expression in 8 t(11;14)-positive, 
22 t(11;14)-negative MM patients and 4 normal controls (N) assessed by GeneChip® Human Gene 2.0ST array. 
P-value obtained by Kruskal-Wallis test.
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expression levels and identified 43 significantly, and all positively, correlated pairs that involve 39 different 
genes and 35 different lncRNAs (combinations selected under criteria of Pearson coefficient >0.4 or <−0.4 and 
p-value < 0.01). Notably, all the 35 lncRNAs belong to the list of 391 unique lncRNAs differentially expressed 
among the four MM subgroups (Table 3).
MM-Gene 
Symbol description Chr. lncRNA R p-value
lncRNA in MM 
subgroup
FBXW7 F-box and WD repeat domain containing 7 4q31 RP11-588K22.2 0.42 0.016 DW
t(11;14)
CCND2 cyclin D2 12p13 CCND2-AS1 0.95 1.50E-16 DW
CUL4A cullin 4A 13q34 GAS6-AS2 0.45 0.011 DW
CCR2 C-C motif chemokine receptor 2 3p21 RP4-555D20.2 0.63 1.22E-04 DW
WWOX WW domain containing oxidoreductase 16q23 RP11-679B19.1RP11-70D24.2
0.53
0.68
0.002
1.77E-05
DW
DW
MAF MAF bZIP transcription factor 16q23 RP11-679B19.1RP11-70D24.2
0.42
0.63
0.016
1.27E-04
DW
DW
RELN reelin 7q22 CTB-107G13.1 0.42 0.017 UP
PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma 7q22 CTB-107G13.1 0.45 0.009 UP
PAX5 paired box 5 9p13 EBLN3 0.59 4.27E-04 UP
KREMEN2 kringle containing transmembrane protein 2 16p13 AC005606.14 0.53 0.002 UP
CCL2 C-C motif chemokine ligand 2 17q12 RP11-848P1.5 0.46 0.008 UP
STAT3 signal transducer and activator of transcription 3 17q21 RARA-AS1 0.52 0.002 UP
RARA retinoic acid receptor alpha 17q21 RARA-AS1 0.70 8.49E-06 UP
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 18q21 RP11-299P2.2 0.42 0.017 UP
HGF hepatocyte growth factor 7q21 AC006145.4 0.45 0.009 DW
t(4;14)
AKT1 AKT serine/threonine kinase 1 14q32 RP11-731F5.2 0.43 0.013 DW
DNMT1 DNA methyltransferase 1 19p13 CTD-3214H19.6 0.41 0.021 DW
CD81 CD81 molecule 11p15 RP11-326C3.2 0.70 9.41E-06 DW
PTGS2 prostaglandin-endoperoxide synthase 2 1q31 GS1-115G20.1 0.71 5.05E-06 UP
TNFRSF1A TNF receptor superfamily member 1A 12p13 RP5-1063M23.2 0.80 4.32E-08 UP
PAK2 p21 (RAC1) activated kinase 2 3q29 LMLN-AS1 0.49 0.005 UP
ADAM9 ADAM metallopeptidase domain 9 8p11 RP11-350N15.6 0.44 0.013 UP
DICER1 dicer 1, ribonuclease III 14q32 RP11-433J8.1 0.41 0.018 UP
PTPN6 protein tyrosine phosphatase, non-receptor type 6 12p13 RP5-1063M23.2 0.94 2.00E-15 UP
BCL9 B-cell CLL/lymphoma 9 1q21 RP11-196G18.22 0.67 2.58E-05 DW
HD
HIST2H3C histone cluster 2 H3 family member c 1q21 RP11-196G18.22 0.53 0.002 DW
ILF2 interleukin enhancer binding factor 2 1q21 ASH1L-AS1 0.59 3.52E-04 DW
DEPTOR DEP domain containing MTOR interacting protein 8q24 KB-1471A8.1 0.73 2.38E-06 DW
P2RX7 purinergic receptor P2X 7 12q24 RP11-347I19.7 0.49 0.005 DW
CIITA class II major histocompatibility complex transactivator 16p13 RP11-490O6.2 0.61 2.10E-04 DW
NES nestin 1q23 RP11-404F10.2 0.41 0.020 DW
MAF trx
FCRL4 Fc receptor like 4 1q23 RP11-404F10.2 0.43 0.015 DW
DKK1 dickkopf WNT signaling pathway inhibitor 1 10q21 PRKG1-AS1 0.51 0.003 DW
MBL2 mannose binding lectin 2 10q21 PRKG1-AS1 0.71 5.70E-06 DW
NCAM1 neural cell adhesion molecule 1 11q23 RP11-629G13.1 0.53 0.002 DW
XPO1 exportin 1 2p15 RP11-373L24.1RP11-568N6.1
0.46
0.53
0.009
0.00
DW
DW
IFNL1 interferon lambda 1 19q13 PCAT19 0.40 0.023 DW
TIMP1 TIMP metallopeptidase inhibitor 1 Xp11 RP6-99M1.3MIR222HG
0.50
0.46
0.003
0.009
DW
DW
HAVCR2 hepatitis A virus cellular receptor 2 5q33 AC008697.1 0.47 0.007 UP
Table 3. Significant correlation among MM-genes and lncRNAs nearer than 4 Mb each other. The last 
column specifies for each lncRNA upregulation (UP) or downregulation (DW) in the specified MM group by 
DE-seq analysis.
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Discussion
In the present study, we have provided an unprecedented view of the lncRNAs expression in MM. As it occurred 
for mRNAs, miRNAs, and snoRNAs6,7,31,32, the natural clustering of whole lncRNAs transcriptional configura-
tion is significantly associated with the major molecular prognostic alterations in MM, namely 11q13, 4p16, 
16q23/20q12 chromosomal translocations, or HD status. In details, for each MM subtype we defined a specific 
and exhaustive lncRNAs expression signature based on the 14,202 lncRNAs currently annotated on GENCODE 
database. In a previous study concerning about 1,800 lncRNAs detectable by microarrays, we had reported a 
number of differentially expressed lncRNAs among the same MM subgroups. However, with very few exceptions 
(MATN1-AS1 upregulated in MM with t(11;14), and CRYM-AS1 and LINC00158 upregulated in MAF translo-
cated patients), RNA-seq data scarcely overlapped with our previous data. This discrepancy can be explained 
in all likelihood by two reason: first, the array annotation was based on a previous version of the LNCipedia 
repository (https://lncipedia.org)33 that had included pseudogenes and miscellaneous RNA within lncRNA 
transcripts, which are conversely excluded in the current study focused on transcripts annotated as “pure” long 
non-coding RNA. Second, very little is still known about the processing and the prevalence of alternative tran-
scripts for many lncRNAs, whose “splicing” products are often roughly defined and/or based on predictions. 
While RNA-seq allowed to evaluate the non-coding genes in their full extension (according to the provided anno-
tations), microarrays evaluation is probe-position dependent and might be therefore affected by the number of 
transcripts in the queried region. This last aspect undoubtedly reinforce the highest accuracy of RNA-seq data for 
complex transcriptome processing. We are aware that the number of samples analyzed in this study does not allow 
drawing definitive conclusion, all the more true in that myeloma patients may share different primary/secondary 
molecular alterations. We kept this in close consideration when the cohort was selected, aimed at being represent-
ative of the major genetic lesions and avoiding as much as possible that confounding variables might affect data in 
differential analysis (graphical legend to the Fig. 1a). To further overcome these limitations, lncRNAs expression 
evaluated by RNA-seq technology was validated by high-density arrays, overall leading to the definition of a com-
prehensive background for future investigations of lncRNAs in plasma cell dyscrasias.
Considering the lncRNAs expression signatures, no information is currently available for the majority of the 
lncRNAs identified. Among the five most significant lncRNAs found differentially expressed in each comparison 
(Table 2), the well-known lncRNA MIAT resulted specifically downregulated in MM carrying t(11;14). Originally 
identified within a susceptible locus for myocardial infarction on chromosome 22q12.1, MIAT was then char-
acterized as the RNA component of specific nuclear bodies where it may affect RNA splicing, ultimately reg-
ulating gene expression34. Recently Sattari et al.35 found MIAT upregulation in leukemia/lymphoma lymphoid 
lineage with mature B-cell phenotype; interestingly, they demonstrated a higher incidence of MIAT upregulation 
in aggressive types of CLL and worst clinical outcome. In addition, this study described a positive feedback regu-
latory loop between MIAT and OCT4, acting on evading apoptotic cell death in malignant mature B cells. Overall, 
these findings suggest an involvement of MIAT in supporting proliferation of the malignant mature B-cells. In this 
perspective, lower MIAT expression in t(11;14)-positive patients might be associated with the better prognosis 
associated with this MM subtype36.
Among the most significant lncRNAs defining the signature of HD-MM, we found the downregulation of 
ASHL1-AS1 and KB-1471A8.1. Both lncRNAs resulted also from the analyses aimed at identifying lncRNAs that 
are located in proximity to, and concordantly expressed with genes important in the context of MM pathology 
(Table 3). In details, ASHL1-AS1 maps 1,89 Mb telomeric to ILF2, overexpressed in MM as a result of 1q21 ampli-
fication. ILF2 overexpression deregulates homologous recombination (HR) by stabilizing the mRNA splicing of 
critical HR effectors, which enables genomic instability, promotes adaptive mechanisms to genotoxic stress, and 
enhances cell survival, thereby promoting drug resistance and disease progression37. As regards KB-1471A8.1, it 
maps at 8q24 antisense to the 5′ region of DEPTOR, a crucial gene in the maintenance of the terminal differentia-
tion of MM cells38. Since the overexpression of DEPTOR in MM has been associated with MAF translocations and 
the expression of CCND1 and CCND3 genes39, the downregulation of KB-1471A8.1 in HD-MM further suggest 
a cis-regulatory connection with DEPTOR.
Finally, among the most significant lncRNAs deregulated in MAF translocated MM, our data unraveled the 
MIR222HG sequence, from the maturation of which originate microRNAs 221 and 222 that were found accord-
ingly downregulated in this MM subtype31. MIR222HG is located at Xp11 about 1.7 Mb telomeric to the TIMP1 
gene encoding an inhibitor of metalloproteinases. As the balance between metalloproteinases and their inhibitors, 
including TIMP1, largely influences cell adhesion, proteolytic shedding, and cell signaling, it will be of great inter-
est to clarify the putative regulation of TIMP1 expression by MIR222HG.
Overall, to our knowledge our study provides the first comprehensive catalogue by RNA-seq of lncRNAs in 
MM, which is highly beneficial as a valuable reference for future research  on their involvement into the patho-
genesis of the disease.
Methods
Samples. The molecular features of the 30 patients at diagnosis included in the study cohort are shown in 
Table 1. PCs purification has been previously described and led to >90% enrichment in all samples [Mattioli, 
Oncogene 2005]. According to already reported FISH procedure40, eight samples showed the t(11;14) translo-
cation, with the consequent overexpression of either CCND1, and a non-hyperdiploid (HD) status; 8 MM were 
HD; seven patients showed high CCND2 levels and the presence of the t(4;14) translocation; and four expressed 
the highest levels of CCND2 in association with either the t(14;16) or t(14;20) translocations. Information on 
17p13 and 13q14 deletions, and gain of 1q arm was also available. Mutation of BRAF, NRAS, KRAS, P53, FAM46C 
and DIS3 were investigated by next-generation sequencing41–44. Written informed consent was obtained from all 
patients in accordance with the declaration of Helsinki. The study was approved by the Ethical Committee of the 
University of Milan (N°24/15, May 06 2015).
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RNA sequencing. Total RNA was extracted from purified PCs by using Trizol reagent. Quantitative assess-
ment of the RNA was performed using Nanodrop ND-1000 Biophotometer (NanoDrop Technologies): the min-
imum OD 260/280 ratio to be considered acceptable is 1.98–2.10. Four-hundred ng of total RNA were used to 
prepare paired-end (PE) cDNA libraries using the TruSeq® RNA Sample Preparation kit for total RNA (Illumina). 
The libraries were sequenced to obtain strand-specific 100 bp PE reads on a HiSeq. 2000 (Illumina). Reads were 
aligned to the human genome using STAR under default conditions and Gencode v25 GTF file. STAR aligner 
was based on splice junctions from the Ensembl database version 87. Transcript abundance was estimated using 
featureCounts (default parameters). FPKM (Fragments Per Kilobase Million) quantification was performed on 
sorted BAM files using cufflinks default procedure. Differentially expressed genes were identified using DeSeq at 
FDR < 0.01, provided that expression across the whole dataset was not null. Quality Control (QC) analysis was 
performed using multiqc tool and the QC metrics were comparable for all samples. The annotation allowed to 
detect 14,202 lncRNAs, including the following Gencode biotypes: lincRNA, antisense, bidirectional promoter 
lncRNA, sense intronic, sense overlapping, 3′ overlapping ncRNA. The expression filter retained 9,540 lncRNAs 
in our dataset.
Gene Expression Profiling. Thirty MM samples and four normal controls (purchased from Voden, Medical 
Instruments IT) were profiled onto GeneChip® Human Gene 2.0 ST arrays (Affymetrix Inc., Santa Clara, CA). 
Total RNA samples were processed according to manufacture’s procedure. Normalized expression values were 
obtained using Robust Multi Array Average (RMA) procedure. A custom annotation pipeline was applied that 
combined GENCODE v25 (Ensembl v87) annotations with the CDF (Chip Definition File) version 21 for gene 
annotations freely available at http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/21.0.0/
genecodeg.asp, in order to withdraw probes that map to regions where ambiguous detection due to transcript 
overlap might occur. Therefrom, the expression levels of Ensembl genes specific for 10138 unique lncRNAs were 
obtained.
All the data have been deposited in the NCBI Gene Expression Omnibus database (GEO; http://www.ncbi.
nlm.nih.gov/geo) and are accessible under accession #GSE109116.
Statistical analysis. Pearson’s correlation as distance and centroid linkage were used in hierarchical agglom-
erative clustering analysis. Conventional statistical tests were applied as reported in the manuscript using stand-
ard packages for R software.
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